|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:activities
|
modulates neurotransmitter activity
|
|
gptkbp:class
|
gptkb:drug
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Company
gptkb:USA
high
Phase 2
promising
|
|
gptkbp:collaborations
|
academic institutions
research organizations
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:developed_by
|
gptkb:Allergan
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
extended-release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0725
|
|
gptkbp:indication
|
social anxiety disorder
generalized anxiety disorder
panic disorder
|
|
gptkbp:ingredients
|
C20 H24 N2 O3 S
|
|
gptkbp:interacts_with
|
gptkb:beer
CY P450 inhibitors
|
|
gptkbp:invention
|
gptkb:Allergan
patented
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
anxiety treatment
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
not yet marketed
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:receives_funding_from
|
gptkb:Company
government grants
private investors
|
|
gptkbp:regulatory_compliance
|
pending
|
|
gptkbp:research_areas
|
mental health
psychiatry
|
|
gptkbp:safety_features
|
well-tolerated
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
drowsiness
insomnia
|
|
gptkbp:social_structure
|
sulfonamide derivative
|
|
gptkbp:status
|
ongoing
|
|
gptkbp:target_audience
|
adults
adolescents
|
|
gptkbp:targets
|
GABA receptors
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:weight
|
372.48 g/mol
|
|
gptkbp:year_created
|
gptkb:2020
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:bfsLayer
|
4
|